efficacy of tirzepatide in phase 2 (GPGB; [14]) and phase 3 (SURPASS-1 The promise of tirzepatide: A

Theyre different from glipizide ER tablets, which are an extended-release (ER) form of the drug

Heres what we know about its timeline: Current status: Phase 3 clinical trials underway Expected FDA submission: Late 2025 or early 2026 Potential approval: Late 2026 to early 2027, though delays are common Market availability: Likely 2027, assuming trials remain positive If youre interested in accessing retatrutide now, you may be able to join a clinical trial

14,15 Residual risk for another cardiovascular event in people with obesity and known heart disease remains despite treatment of known cardiovascular risk factors such as high blood pressure and high cholesterol according to standard of care treatments

This timeline applies even if you use only a small amount of the dose